For all those who don’t know, Illumina is one of the leading developers, manufacturers, and marketers of biological tools and integrated systems for large-scale analysis of genetic variation and function.

Reuters reported that the Gene sequencing company Illumina Inc. is going after the next big advance in cancer detection, and is working to develop a universal blood test that identifies early-stage cancers in people with no symptoms of the disease.

The company basically enables studies that were not even imaginable a few years ago, and moves us closer to the realization of personalized medicine, which is the “tailoring” of medical treatment according to the patient’s predicted response or risk of disease.

However, the fight against cancer has been ongoing for decades now, and it seems that scientists are no longer concerned with only curing the disease, rather than catching it early on, at its beginning, for a higher possibility of treatment being successful.

Furthermore, on Sunday, San Diego-based Illumina said it would form a new company, called Grail, with more than $100 million in (SeriesA) financing, in which Illumina will be the major owner.

Key investors include technology giants Bill Gates, founder of Microsoft, and Jeff Bezos, founder of Amazon.com, as well as backing from ARCH Venture Partners and Sutter Hill Ventures.

Moreover, with the rapid advances in technology taking place, it is critical to offer solutions that are not only innovative, but flexible and scalable, with industry-leading support and service.

Illumina has developed a comprehensive line of products that addresses the scale of experimentation and scope of functional analysis to advance disease research, drug development, and the development of molecular tests.